FutureMeds to Open Poznan Dedicated Research Site in March 2027

The new dedicated site will extend FutureMeds’ reach into western Poland and add clinical trial capacity within the metro area of more than 1 million people.

FutureMeds to open a dedicated clinical research site in Poznan in March 2027, continuing the expansion of its site network across Europe.

The new location will give Sponsors and CROs access to an additional patient population in western Poland.

“The expansion into Poznan is a natural next step in our growth strategy. Poznan is one of Poland’s largest academic and health care hubs, offering access to experienced medical professionals and a large patient population. Establishing a presence here strengthens our nationwide network and allows us to better support sponsors with faster recruitment and broader therapeutic-area capabilities.”

— Dr Piotr Rozpondek, Managing Director at FutureMeds Poland

Why Poznan

The wider Poznan metropolitan area is home to more than 1 million people. Its established hospitals, medical institutions, and academic community create opportunities to work with experienced physicians and research professionals.

The city also has strong road, rail, and public transportation links, helping patients reach the site from Poznan and surrounding communities.

The site is being planned to support studies across multiple therapeutic areas. Details of investigators, initial capabilities, and study portfolio will be announced as the opening approaches.

Continuing the growth of FutureMeds Poland

The announcement follows continued expansion during 2026, with FutureMeds Poland developing its site network, operational capacity and portfolio of clinical studies.

The site is scheduled to become operational in March 2027. Sponsors and CROs planning studies in Poland can contact FutureMeds to discuss its anticipated availability and potential fit with upcoming protocols.